Blood Screening Market By Product (Instruments, Kits and Reagents), By Technology (NAT Technology, Immunoassays), By End User (Blood Banks, Hospitals): Global Opportunity Analysis and Industry Forecast, 2023-2032
The global blood screening market was valued at $2.4 billion in 2022 and is projected to reach $4.9 billion by 2032, registering a CAGR of 7.5% from 2023 to 2032. Blood screening is the process of testing the donated blood prior to transfusion to ensure that recipients receive the safest possible blood products. The objective of blood screening is to detect markers of infection to prevent the release of infected blood and blood components for clinical use. Blood screening strategies are designed to assure the safety of blood units. Based on the screening process, the blood is either used for medical applications or discarded if any infectious pathogen was found in it.
The factors driving the growth of the market include rise in demand for donated blood and blood related products for medical applications, surge in number of blood donations globally, and strict protocols by regulatory body for screening of blood to ensure safe transfusion.
The rise in demand for donated blood and blood-related products for medical applications has emerged as a major driving force behind the growth of the blood screening market. This increased demand can be attributed to several factors, including the growing prevalence of chronic diseases, the expansion of medical procedures and surgeries, and the need for blood transfusions in emergency situations. For instance, according to 2022 report by U.S. Blood Statistics, in U.S. in every 2 second donated blood is used for medical purpose. The demand for blood products has surged, as healthcare systems advance worldwide, creating a significant need for stringent blood screening processes to ensure the safety of both donors and recipients. Blood screening plays a pivotal role in identifying and eliminating infectious agents such as HIV, hepatitis, and other blood-borne pathogens, thereby reducing the risk of transmission and improving the overall safety of blood transfusions. Thus, the rise in demand for donated blood is expected to drive the growth of the blood screening products to ensure safe transfusion of the blood.
Furthermore, the strict protocols of regulatory bodies towards screening of donated blood are also expected to drive the growth of the market. These regulatory frameworks are designed to ensure the safety of donated blood and protect both the donors and recipients. The protocols encompass various aspects of the blood screening process, including donor eligibility criteria, sample collection, testing methodologies, and post-screening measures. By adhering to these rigorous regulations, blood banks and screening facilities can maintain a high level of trust and confidence in the quality of the blood supply. According to 2023 report by World Health Organization, screening for HIV, hepatitis B, hepatitis C, and syphilis in donated blood should be mandatory. The same report mentioned that 99.8% of the donations in high-income countries and 99.9% in upper-middle-income countries are screened following basic quality procedures. Thus, the measures taken by the public and private organizations in regulating and ensuring the blood screening of every donated blood unit is expected to drive the demand for the blood screening products.
In addition, the surge in number of blood donations globally has emerged as a significant driver for the blood screening market. Over the years, there has been a growing awareness about the importance of regular blood donations to meet the increasing demand for blood and its components in healthcare settings, particularly for medical procedures, surgeries, and the treatment of various diseases. For instance, according to World Health Organization, in 2022, a total of 118.8 million blood donations were collected globally. This increased awareness, coupled with advancements in medical technology, has encouraged a substantial rise in voluntary and organized blood donation campaigns worldwide. As a result, the need for rigorous and efficient blood screening procedures has become important to ensure the safety of the donated blood supply. Thus, the rise in blood donations globally is expected to drive the growth of the blood screening market. However, regulatory hurdles and high cost of blood screening instruments are projected to restrain the growth of the market.
The blood screening market is segmented on the basis of product, technology, end use, and region. By product, the market is classified into instruments and kits and reagents. By technology, the market is categorized into NAT technology, immunoassay. By end user, the market is bifurcated into hospitals and blood banks. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global blood screening market include F. Hoffmann-La Roche Ltd., Grifols, S.A., Abbott Laboratories, Bio-Rad Laboratories, Inc., Danaher Corporation, DiaSorin S.p.A., Siemens AG, Avioq, Inc, QuidelOrtho Corporation and Alive DX.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the blood screening market analysis from 2022 to 2032 to identify the prevailing blood screening market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the blood screening market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global blood screening market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
Instruments
Kits and Reagents
By End User
Blood Banks
Hospitals
By Technology
NAT Technology
Type
Transcription Mediated Amplification (TMA)
Real time PCR
NGS
Immunoassays
Type
Enzyme immunoassays (EIAs)
Chemiluminescent immunoassays (CLIAs)
Particle agglutination (PA) assays
Rapid assays
Western Bloat
ELSA
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
South Arabia
South Africa
Rest of LAMEA
Key Market Players
Grifols, S.A.
Abbott Laboratories
Danaher Corporation
DiaSorin S.p.A.
Avioq, Inc.
F. Hoffmann-La Roche Ltd.
Bio-Rad Laboratories, Inc.
Siemens AG
Alive DX
QuidelOrtho Corporation.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Rise in demand for donated blood for medical applications.
- 3.4.1.2. Surge in number of blood donations globally.
- 3.4.2. Restraints
- 3.4.2.1. Regulatory Hurdles.
- 3.4.3. Opportunities
- 3.4.3.1. Rise in awareness about diseases transmitted through transfusion.
- CHAPTER 4: BLOOD SCREENING MARKET, BY PRODUCT
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Instruments
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Kits and Reagents
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- CHAPTER 5: BLOOD SCREENING MARKET, BY TECHNOLOGY
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. NAT Technology
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.2.4. NAT Technology Blood Screening Market by Type
- 5.3. Immunoassays
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.3.4. Immunoassays Blood Screening Market by Type
- CHAPTER 6: BLOOD SCREENING MARKET, BY END USER
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Blood Banks
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Hospitals
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- CHAPTER 7: BLOOD SCREENING MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Product
- 7.2.3. Market size and forecast, by Technology
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Market size and forecast, by Product
- 7.2.5.1.2. Market size and forecast, by Technology
- 7.2.5.1.3. Market size and forecast, by End User
- 7.2.5.2. Canada
- 7.2.5.2.1. Market size and forecast, by Product
- 7.2.5.2.2. Market size and forecast, by Technology
- 7.2.5.2.3. Market size and forecast, by End User
- 7.2.5.3. Mexico
- 7.2.5.3.1. Market size and forecast, by Product
- 7.2.5.3.2. Market size and forecast, by Technology
- 7.2.5.3.3. Market size and forecast, by End User
- 7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Product
- 7.3.3. Market size and forecast, by Technology
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Market size and forecast, by Product
- 7.3.5.1.2. Market size and forecast, by Technology
- 7.3.5.1.3. Market size and forecast, by End User
- 7.3.5.2. France
- 7.3.5.2.1. Market size and forecast, by Product
- 7.3.5.2.2. Market size and forecast, by Technology
- 7.3.5.2.3. Market size and forecast, by End User
- 7.3.5.3. UK
- 7.3.5.3.1. Market size and forecast, by Product
- 7.3.5.3.2. Market size and forecast, by Technology
- 7.3.5.3.3. Market size and forecast, by End User
- 7.3.5.4. Italy
- 7.3.5.4.1. Market size and forecast, by Product
- 7.3.5.4.2. Market size and forecast, by Technology
- 7.3.5.4.3. Market size and forecast, by End User
- 7.3.5.5. Spain
- 7.3.5.5.1. Market size and forecast, by Product
- 7.3.5.5.2. Market size and forecast, by Technology
- 7.3.5.5.3. Market size and forecast, by End User
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Market size and forecast, by Product
- 7.3.5.6.2. Market size and forecast, by Technology
- 7.3.5.6.3. Market size and forecast, by End User
- 7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Product
- 7.4.3. Market size and forecast, by Technology
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. China
- 7.4.5.1.1. Market size and forecast, by Product
- 7.4.5.1.2. Market size and forecast, by Technology
- 7.4.5.1.3. Market size and forecast, by End User
- 7.4.5.2. Japan
- 7.4.5.2.1. Market size and forecast, by Product
- 7.4.5.2.2. Market size and forecast, by Technology
- 7.4.5.2.3. Market size and forecast, by End User
- 7.4.5.3. India
- 7.4.5.3.1. Market size and forecast, by Product
- 7.4.5.3.2. Market size and forecast, by Technology
- 7.4.5.3.3. Market size and forecast, by End User
- 7.4.5.4. Australia
- 7.4.5.4.1. Market size and forecast, by Product
- 7.4.5.4.2. Market size and forecast, by Technology
- 7.4.5.4.3. Market size and forecast, by End User
- 7.4.5.5. South Korea
- 7.4.5.5.1. Market size and forecast, by Product
- 7.4.5.5.2. Market size and forecast, by Technology
- 7.4.5.5.3. Market size and forecast, by End User
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Market size and forecast, by Product
- 7.4.5.6.2. Market size and forecast, by Technology
- 7.4.5.6.3. Market size and forecast, by End User
- 7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Product
- 7.5.3. Market size and forecast, by Technology
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Market size and forecast, by Product
- 7.5.5.1.2. Market size and forecast, by Technology
- 7.5.5.1.3. Market size and forecast, by End User
- 7.5.5.2. South Arabia
- 7.5.5.2.1. Market size and forecast, by Product
- 7.5.5.2.2. Market size and forecast, by Technology
- 7.5.5.2.3. Market size and forecast, by End User
- 7.5.5.3. South Africa
- 7.5.5.3.1. Market size and forecast, by Product
- 7.5.5.3.2. Market size and forecast, by Technology
- 7.5.5.3.3. Market size and forecast, by End User
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Market size and forecast, by Product
- 7.5.5.4.2. Market size and forecast, by Technology
- 7.5.5.4.3. Market size and forecast, by End User
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product mapping of top 10 player
- 8.4. Competitive dashboard
- 8.5. Competitive heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. F. Hoffmann-La Roche Ltd.
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.2. Grifols, S.A.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
- 9.3. Abbott Laboratories
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.4. Bio-Rad Laboratories, Inc.
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.4.7. Key strategic moves and developments
- 9.5. Danaher Corporation
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.6. DiaSorin S.p.A.
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
- 9.7. Siemens AG
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. Avioq, Inc.
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.9. Alive DX
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.10. QuidelOrtho Corporation.
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
- LIST OF TABLES
- TABLE 01. GLOBAL BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 02. BLOOD SCREENING MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
- TABLE 03. BLOOD SCREENING MARKET FOR KITS AND REAGENTS, BY REGION, 2022-2032 ($MILLION)
- TABLE 04. GLOBAL BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 05. BLOOD SCREENING MARKET FOR NAT TECHNOLOGY, BY REGION, 2022-2032 ($MILLION)
- TABLE 06. GLOBAL NAT TECHNOLOGY BLOOD SCREENING MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 07. BLOOD SCREENING MARKET FOR IMMUNOASSAYS, BY REGION, 2022-2032 ($MILLION)
- TABLE 08. GLOBAL IMMUNOASSAYS BLOOD SCREENING MARKET, BY TYPE, 2022-2032 ($MILLION)
- TABLE 09. GLOBAL BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 10. BLOOD SCREENING MARKET FOR BLOOD BANKS, BY REGION, 2022-2032 ($MILLION)
- TABLE 11. BLOOD SCREENING MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
- TABLE 12. BLOOD SCREENING MARKET, BY REGION, 2022-2032 ($MILLION)
- TABLE 13. NORTH AMERICA BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 14. NORTH AMERICA BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 15. NORTH AMERICA BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 16. NORTH AMERICA BLOOD SCREENING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 17. U.S. BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 18. U.S. BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 19. U.S. BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 20. CANADA BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 21. CANADA BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 22. CANADA BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 23. MEXICO BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 24. MEXICO BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 25. MEXICO BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 26. EUROPE BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 27. EUROPE BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 28. EUROPE BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 29. EUROPE BLOOD SCREENING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 30. GERMANY BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 31. GERMANY BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 32. GERMANY BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 33. FRANCE BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 34. FRANCE BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 35. FRANCE BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 36. UK BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 37. UK BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 38. UK BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 39. ITALY BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 40. ITALY BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 41. ITALY BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 42. SPAIN BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 43. SPAIN BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 44. SPAIN BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 45. REST OF EUROPE BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 46. REST OF EUROPE BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 47. REST OF EUROPE BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 48. ASIA-PACIFIC BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 49. ASIA-PACIFIC BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 50. ASIA-PACIFIC BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 51. ASIA-PACIFIC BLOOD SCREENING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 52. CHINA BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 53. CHINA BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 54. CHINA BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 55. JAPAN BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 56. JAPAN BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 57. JAPAN BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 58. INDIA BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 59. INDIA BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 60. INDIA BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 61. AUSTRALIA BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 62. AUSTRALIA BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 63. AUSTRALIA BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 64. SOUTH KOREA BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 65. SOUTH KOREA BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 66. SOUTH KOREA BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 67. REST OF ASIA-PACIFIC BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 68. REST OF ASIA-PACIFIC BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 69. REST OF ASIA-PACIFIC BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 70. LAMEA BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 71. LAMEA BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 72. LAMEA BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 73. LAMEA BLOOD SCREENING MARKET, BY COUNTRY, 2022-2032 ($MILLION)
- TABLE 74. BRAZIL BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 75. BRAZIL BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 76. BRAZIL BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 77. SOUTH ARABIA BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 78. SOUTH ARABIA BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 79. SOUTH ARABIA BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 80. SOUTH AFRICA BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 81. SOUTH AFRICA BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 82. SOUTH AFRICA BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 83. REST OF LAMEA BLOOD SCREENING MARKET, BY PRODUCT, 2022-2032 ($MILLION)
- TABLE 84. REST OF LAMEA BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022-2032 ($MILLION)
- TABLE 85. REST OF LAMEA BLOOD SCREENING MARKET, BY END USER, 2022-2032 ($MILLION)
- TABLE 86. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
- TABLE 87. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
- TABLE 88. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
- TABLE 89. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
- TABLE 90. GRIFOLS, S.A.: KEY EXECUTIVES
- TABLE 91. GRIFOLS, S.A.: COMPANY SNAPSHOT
- TABLE 92. GRIFOLS, S.A.: PRODUCT SEGMENTS
- TABLE 93. GRIFOLS, S.A.: PRODUCT PORTFOLIO
- TABLE 94. GRIFOLS, S.A.: KEY STRATERGIES
- TABLE 95. ABBOTT LABORATORIES: KEY EXECUTIVES
- TABLE 96. ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 97. ABBOTT LABORATORIES: PRODUCT SEGMENTS
- TABLE 98. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 99. BIO-RAD LABORATORIES, INC. : KEY EXECUTIVES
- TABLE 100. BIO-RAD LABORATORIES, INC. : COMPANY SNAPSHOT
- TABLE 101. BIO-RAD LABORATORIES, INC. : PRODUCT SEGMENTS
- TABLE 102. BIO-RAD LABORATORIES, INC. : PRODUCT PORTFOLIO
- TABLE 103. BIO-RAD LABORATORIES, INC. : KEY STRATERGIES
- TABLE 104. DANAHER CORPORATION: KEY EXECUTIVES
- TABLE 105. DANAHER CORPORATION: COMPANY SNAPSHOT
- TABLE 106. DANAHER CORPORATION: PRODUCT SEGMENTS
- TABLE 107. DANAHER CORPORATION: PRODUCT PORTFOLIO
- TABLE 108. DIASORIN S.P.A.: KEY EXECUTIVES
- TABLE 109. DIASORIN S.P.A.: COMPANY SNAPSHOT
- TABLE 110. DIASORIN S.P.A.: PRODUCT SEGMENTS
- TABLE 111. DIASORIN S.P.A.: PRODUCT PORTFOLIO
- TABLE 112. DIASORIN S.P.A.: KEY STRATERGIES
- TABLE 113. SIEMENS AG: KEY EXECUTIVES
- TABLE 114. SIEMENS AG: COMPANY SNAPSHOT
- TABLE 115. SIEMENS AG: PRODUCT SEGMENTS
- TABLE 116. SIEMENS AG: PRODUCT PORTFOLIO
- TABLE 117. AVIOQ, INC.: KEY EXECUTIVES
- TABLE 118. AVIOQ, INC.: COMPANY SNAPSHOT
- TABLE 119. AVIOQ, INC.: PRODUCT SEGMENTS
- TABLE 120. AVIOQ, INC.: SERVICE SEGMENTS
- TABLE 121. AVIOQ, INC.: PRODUCT PORTFOLIO
- TABLE 122. ALIVE DX: KEY EXECUTIVES
- TABLE 123. ALIVE DX: COMPANY SNAPSHOT
- TABLE 124. ALIVE DX: PRODUCT SEGMENTS
- TABLE 125. ALIVE DX: PRODUCT PORTFOLIO
- TABLE 126. QUIDELORTHO CORPORATION.: KEY EXECUTIVES
- TABLE 127. QUIDELORTHO CORPORATION.: COMPANY SNAPSHOT
- TABLE 128. QUIDELORTHO CORPORATION.: PRODUCT SEGMENTS
- TABLE 129. QUIDELORTHO CORPORATION.: PRODUCT PORTFOLIO
- LIST OF FIGURES
- FIGURE 01. BLOOD SCREENING MARKET, 2022-2032
- FIGURE 02. SEGMENTATION OF BLOOD SCREENING MARKET,2022-2032
- FIGURE 03. TOP IMPACTING FACTORS IN BLOOD SCREENING MARKET (2022 TO 2032)
- FIGURE 04. TOP INVESTMENT POCKETS IN BLOOD SCREENING MARKET (2023-2032)
- FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
- FIGURE 06. LOW THREAT OF NEW ENTRANTS
- FIGURE 07. LOW THREAT OF SUBSTITUTES
- FIGURE 08. LOW INTENSITY OF RIVALRY
- FIGURE 09. LOW BARGAINING POWER OF BUYERS
- FIGURE 10. GLOBAL BLOOD SCREENING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 11. BLOOD SCREENING MARKET, BY PRODUCT, 2022 AND 2032(%)
- FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BLOOD SCREENING MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BLOOD SCREENING MARKET FOR KITS AND REAGENTS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 14. BLOOD SCREENING MARKET, BY TECHNOLOGY, 2022 AND 2032(%)
- FIGURE 15. COMPARATIVE SHARE ANALYSIS OF BLOOD SCREENING MARKET FOR NAT TECHNOLOGY, BY COUNTRY 2022 AND 2032(%)
- FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BLOOD SCREENING MARKET FOR IMMUNOASSAYS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 17. BLOOD SCREENING MARKET, BY END USER, 2022 AND 2032(%)
- FIGURE 18. COMPARATIVE SHARE ANALYSIS OF BLOOD SCREENING MARKET FOR BLOOD BANKS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BLOOD SCREENING MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
- FIGURE 20. BLOOD SCREENING MARKET BY REGION, 2022 AND 2032(%)
- FIGURE 21. U.S. BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 22. CANADA BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 23. MEXICO BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 24. GERMANY BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 25. FRANCE BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 26. UK BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 27. ITALY BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 28. SPAIN BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 29. REST OF EUROPE BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 30. CHINA BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 31. JAPAN BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 32. INDIA BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 33. AUSTRALIA BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 34. SOUTH KOREA BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 35. REST OF ASIA-PACIFIC BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 36. BRAZIL BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 37. SOUTH ARABIA BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 38. SOUTH AFRICA BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 39. REST OF LAMEA BLOOD SCREENING MARKET, 2022-2032 ($MILLION)
- FIGURE 40. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
- FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
- FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
- FIGURE 43. PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 44. COMPETITIVE DASHBOARD
- FIGURE 45. COMPETITIVE HEATMAP: BLOOD SCREENING MARKET
- FIGURE 46. TOP PLAYER POSITIONING, 2022
- FIGURE 47. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
- FIGURE 48. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 49. GRIFOLS, S.A.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 50. GRIFOLS, S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 51. GRIFOLS, S.A.: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 52. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
- FIGURE 53. ABBOTT LABORATORIES: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
- FIGURE 54. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 55. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 56. BIO-RAD LABORATORIES, INC. : NET SALES, 2020-2022 ($MILLION)
- FIGURE 57. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 58. BIO-RAD LABORATORIES, INC. : REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 59. DANAHER CORPORATION: NET SALES, 2020-2022 ($MILLION)
- FIGURE 60. DANAHER CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 61. DANAHER CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 62. DIASORIN S.P.A.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 63. DIASORIN S.P.A.: REVENUE SHARE BY REGION, 2021 (%)
- FIGURE 64. SIEMENS AG: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 65. SIEMENS AG: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
- FIGURE 66. SIEMENS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 67. SIEMENS AG: REVENUE SHARE BY REGION, 2022 (%)
- FIGURE 68. QUIDELORTHO CORPORATION.: NET REVENUE, 2020-2022 ($MILLION)
- FIGURE 69. QUIDELORTHO CORPORATION.: REVENUE SHARE BY SEGMENT, 2022 (%)
- FIGURE 70. QUIDELORTHO CORPORATION.: REVENUE SHARE BY REGION, 2022 (%)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook